MIRM Insider Trading Activity and SEC Form 4 Filings
MIRM insider trading summary
Over the past 12 months, insiders at Mirum Pharmaceuticals, Inc. (MIRM) reported 60 sales worth $44.0M by 7 insiders and 1 open-market purchase worth $9.0M by 1 insider on SEC Form 4. Net insider selling was $35.0M.
Latest MIRM insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 4, 2026 | Christopher Peetz | Chief Executive Officer | Sell | $1.8M (20,000 @ $90.00) |
| Sep 14, 2026 | Eric Bjerkholt | Chief Financial Officer | Sell | $978K (9,943 @ $98.37) |
| Sep 2, 2026 | Jolanda Howe | SVP, Global Controller | Sell | $66K (658 @ $100.00) |
| Sep 1, 2026 | Christopher Peetz | Chief Executive Officer | Sell | $815K (8,312 @ $98.08) |
| Sep 1, 2026 | Christopher Peetz | Chief Executive Officer | Sell | $2.1M (21,688 @ $98.91) |
| Aug 18, 2026 | Jolanda Howe | SVP, Global Controller | Sell | $4.0M (40,000 @ $100.00) |
| Aug 11, 2026 | Eric Bjerkholt | Chief Financial Officer | Sell | $600K (6,001 @ $99.90) |
| Aug 10, 2026 | Christopher Peetz | Chief Executive Officer | Sell | $230K (2,300 @ $100.14) |
| Aug 10, 2026 | Christopher Peetz | Chief Executive Officer | Sell | $1.2M (11,683 @ $98.51) |
| Aug 10, 2026 | Christopher Peetz | Chief Executive Officer | Sell | $597K (6,017 @ $99.25) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.